Needham & Company Gives Buy Rating to Optimer Pharmaceutic (OPTR)

By admin | 6 years ago

Optimer Pharmaceutic (NASDAQ: OPTR)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company in a report released on Friday.

Shares of Optimer Pharmaceutic traded up 2.99% during mid-day trading on Friday, hitting $15.49. Optimer Pharmaceutic has a one year low of $6.81 and a one year high of $17.95. The company’s market cap is $723.7 million.

Optimer Pharmaceutic last issued its quarterly earnings data on Thursday, May 10th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.17. The company’s quarterly revenue was down 79.2% on a year-over-year basis. On average, analysts predict that Optimer Pharmaceutic will post $-0.43 earnings per share next quarter.

A number of other analysts have also recently weighed in on OPTR. Analysts at Zacks reiterated a “neutral” rating on shares of Optimer Pharmaceutic in a research note to investors on Thursday, April 12nd. They now have a $14.00 price target on the stock. Separately, analysts at Oppenheimer (NYSE: OPY) raised their price target on shares of Optimer Pharmaceutic to $20.00 in a research note to investors on Friday, March 30th.

Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products.

About the author